Omnicell (OMCL) 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'OMNICELL, Inc	'
Entity Central Index Key	'0000926326	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	35,604,480
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$104,187	$104,531
Accounts receivable, net of allowances of $1,247 and $490, respectively	95,167	58,597
Inventories	31,847	31,457
Prepaid expenses	18,221	18,883
Deferred tax assets	12,684	12,635
Other current assets	6,262	7,675
Total current assets	268,368	233,778
Property and equipment, net	37,688	35,254
Non-current net investment in sales-type leases	10,823	11,485
Goodwill	123,090	111,343
Intangible assets, net	84,075	81,602
Non-current deferred tax assets	975	1,102
Other assets	22,294	17,937
Total assets	547,313	492,501
Current liabilities:	'	'
Accounts payable	23,202	16,471
Accrued compensation	13,071	19,604
Accrued liabilities	17,073	13,746
Deferred service revenue	22,672	22,626
Deferred gross profit	35,542	19,957
Total current liabilities	111,560	92,404
Non-current deferred service revenue	20,368	17,763
Non-current deferred tax liabilities	30,471	28,162
Other long-term liabilities	6,013	5,175
Stockholders’ equity:	168,412	143,504
Stockholders’ equity:	'	'
Total stockholders’ equity	378,901	348,997
Total liabilities and stockholders’ equity	$547,313	$492,501

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowances	$1,247	$490

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Product revenues	$92,229	$75,508	$260,053	$220,325
Services and other revenues	20,314	18,531	59,306	54,510
Total revenues	112,543	94,039	319,359	274,835
Cost of revenues:	'	'	'	'
Cost of product revenues	44,510	33,977	124,413	103,810
Cost of services and other revenues	8,487	8,022	24,865	24,250
Total cost of revenues	52,997	41,999	149,278	128,060
Gross profit	59,546	52,040	170,081	146,775
Operating expenses:	'	'	'	'
Research and development	7,078	6,561	19,670	21,665
Selling, general and administrative	38,871	34,762	114,302	100,866
Total operating expenses	45,949	41,323	133,972	122,531
Income from operations	13,597	10,717	36,109	24,244
Interest and other income (expense), net	-706	25	-1,003	-134
Income before provision for income taxes	12,891	10,742	35,106	24,110
Provision for income taxes	5,591	2,987	13,824	6,954
Net income	$7,300	$7,755	$21,282	$17,156
Net income per share:	'	'	'	'
Net income per share-basic (in dollars per share)	$0.20	$0.22	$0.60	$0.50
Net income per share - diluted (in dollars per share)	$0.20	$0.21	$0.58	$0.48
Weighted average shares outstanding:	'	'	'	'
Basic (in shares)	35,994	35,133	35,634	34,499
Diluted (in shares)	36,832	36,190	36,617	35,466

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income	$7,300	$7,755	$21,282	$17,156
Other comprehensive income:	'	'	'	'
Change in fair value of foreign currency forward contracts	0	0	0	-65
Foreign currency translation adjustment	-669	217	-550	21
Other comprehensive income (loss)	-669	217	-550	-44
Comprehensive income	$6,631	$7,972	$20,732	$17,112

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Statement of Cash Flows [Abstract]	'	'
Acquistiion consideration accrued as goodwill and accrued liabilities	'	$0
Cash flows from operating activities:	'	'
Net income	21,282	17,156
Adjustments to reconcile net income to net cash provided by operating activities, net of business acquisition	'	'
Depreciation and amortization	14,705	13,732
Loss on disposal of fixed assets	221	289
Impairment of software development costs	0	1,759
Provision for receivable allowance	850	110
Share-based compensation expense	8,610	8,387
Income tax benefits from employee stock plans	4,065	1,707
Excess tax benefits from employee stock plans	-4,456	-2,827
Provision for excess and obsolete inventories	450	911
Deferred income taxes	1,307	-737
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	-35,028	-9,004
Inventories	1,301	-4,713
Prepaid expenses	1,015	-1,661
Other current assets	1,412	-394
Non-current net investment in sales-type leases	677	1,313
Other assets	360	307
Accounts payable	5,420	6,462
Accrued compensation	-6,533	1,263
Accrued liabilities	-416	2,031
Deferred service revenue	2,650	-403
Deferred gross profit	15,585	4,434
Other long-term liabilities	838	615
Net cash provided by operating activities	34,315	40,737
Cash flows from investing activities:	'	'
Acquisition of intangible assets and intellectual property	-236	-225
Software development for external use	-7,925	-5,694
Purchases of property and equipment	-10,151	-7,817
Business acquisition, net of cash acquired	-19,749	0
Net cash used in investing activities	-38,061	-13,736
Cash flows from financing activities:	'	'
Proceeds from issuances under stock-based compensation plans	18,157	24,020
Employees' taxes paid related to restricted stock units	-2,023	0
Common stock repurchases	-17,052	0
Excess tax benefits from employee stock plans	4,456	2,827
Net cash provided by financing activities	3,538	26,847
Effect of exchange rate changes on cash and cash equivalents	-136	29
Net increase (decrease) in cash and cash equivalents	-344	53,877
Cash and cash equivalents at beginning of period	104,531	62,313
Cash and cash equivalents at end of period	$104,187	$116,190

Net_Income_Per_Share

Net Income Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Income Per Share	'
		Net Income Per Share
	Basic net income per share is computed by dividing net income for the period by the weighted average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Since their impact is anti-dilutive, we excluded 426,974 and 364,450 shares, respectively, from the calculations of diluted net income per share for the three and nine months ended September 30, 2014 and 465,301 and 1,178,755 shares, respectively, from the same calculations for the three and nine months ended September 30, 2013.
	The calculation of basic and diluted net income per share is as follows (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Basic:
	Net income	$	7,300	$	7,755	$	21,282	$	17,156
	Weighted average shares outstanding — basic	35,994		35,133		35,634		34,499
	Net income per share — basic	$	0.2	$	0.22	$	0.6	$	0.5
	Diluted:
	Net income	$	7,300	$	7,755	$	21,282	$	17,156
	Weighted average shares outstanding — basic	35,994		35,133		35,634		34,499
	Add: Dilutive effect of employee stock plans	838		1,057		983		967
	Weighted average shares outstanding — diluted	36,832		36,190		$	36,617	35,466
	Net income per share — diluted	$	0.2	$	0.21	$	0.58	$	0.48

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	Organization and Summary of Significant Accounting Policies
	Description of the Company. Omnicell, Inc. ("Omnicell," "our," "us," "we," or the "Company") was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. Our major products are automated medication supply control systems and medical adherence solutions which are sold in our principal market, which is the healthcare industry. Our market is primarily located in the United States and Canada.
	In 2012, we acquired Medication Technologies, Inc. ("MTS"), a provider of automated and semi-automated equipment to assist institutional and retail pharmacists in filling medication orders into blister cards, the primary method of medication control in non-acute care settings. MTS is part of our Medication Adherence segment which consists of all the products we sell to fulfill medication adherence needs through blister cards, blister card packaging equipment, and related software.
	In August of 2014, we acquired Surgichem Limited ("Surgichem"), a provider of medication adherence solutions to the non-acute care market in the United Kingdom ("UK"). Surgichem supplies its monitored dosage systems to a network of over 3,200 independent pharmacies and UK pharmacy chains. Surgichem is expected to complement our Medication Adherence segment. For further information, please see Note 7, Business Acquisition.
	Basis of presentation. These interim condensed consolidated financial statements are unaudited but reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of Omnicell and our subsidiaries as of September 30, 2014, the results of our operations and comprehensive income for the three and nine months ended September 30, 2014 and 2013 and our cash flows for the nine months ended September 30, 2014 and 2013. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	Our results of operations, comprehensive income for the three and nine months ended September 30, 2014 and cash flows for the nine months ended September 30, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014, or for any future period.
	Use of estimates. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, valuation of goodwill and purchased intangibles, valuation of long-lived assets and accounting for income taxes.
	Principles of consolidation. The condensed consolidated financial statements include the accounts of our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.
	Concentration of credit risk. Financial instruments that may potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents are maintained with several financial institutions and may exceed the amount of insurance provided on such balances. The majority of our accounts receivable are derived from sales to customers for commercial applications. We perform ongoing credit evaluations of our customers’ financial condition and limit the amount of credit extended when deemed necessary but generally require no collateral. We maintain reserves for potential credit losses. Our products are broadly distributed and there was no single customer accounting for 10% or more of revenues in the three and nine months ended September 30, 2014 and 2013. Additionally, there was no single customer accounting for 10% or more of accounts receivable at September 30, 2014 or December 31, 2013. We believe that we have no significant concentrations of credit risk at September 30, 2014.
	Dependence on suppliers. We have a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in our hardware products. There are no minimum purchase requirements. The contract may be terminated by either the supplier or by us without cause and at any time upon delivery of two months’ notice. Purchases from this supplier for the three months ended September 30, 2014 and 2013 totaled approximately $11.0 million and $8.6 million, respectively, and $28.2 million and $22.5 million for the nine months ended September 30, 2014 and 2013, respectively.
	There have been no material changes in our significant accounting policies as of and for the three and nine months ended September 30, 2014, compared to the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2013.
	Recently Adopted Accounting Standards
	In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ("ASU 2013-11"). ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. We adopted the amendments in ASU 2013-11 in the first quarter of 2014. This update did not have a significant impact on our financial position, operating results or cash flows.
	Recently Issued Accounting Standards
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers: Topic 606 ("ASU 2014-09"). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. Companies may use either of two methods: (i) full retrospective application to each prior reporting period presented with the option to elect certain practical expedients defined within ASU 2014-09; or (ii) modified retrospective application with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. ASU 2014-09 is effective for us in the first quarter of 2017 and we are currently evaluating the impact of our pending adoption on our consolidated financial statements.

Cash_and_Cash_Equivalents_and_

Cash and Cash Equivalents and Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents and Fair Value of Financial Instruments	'
	Cash and Cash Equivalents and Fair Value of Financial Instruments
	Cash and cash equivalents consist of the following significant asset investment classes as of September 30, 2014 and December 31, 2013 (in thousands):
		September 30, 2014
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	42,522	$	—	$	—	$	42,522	$	42,522	N/A
	Money market fund	61,665		—		—		61,665		61,665		Available-for-sale
	Total cash and cash equivalents	$	104,187	$	—	$	—	$	104,187	$	104,187
	c	December 31, 2013
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	38,823	$	—	$	—	$	38,823	$	38,823	N/A
	Money market fund	65,708		—		—		65,708		65,708		Available-for-sale
	Total cash and cash equivalents	$	104,531	$	—	$	—	$	104,531	$	104,531
	The money market fund is a daily-traded cash equivalent with a price of $1.00, making it a Level 1 asset class, and its carrying cost closely approximates fair value. As demand deposit (cash) balances vary with the timing of collections and payments, the money market fund can cover any surplus or deficit, and thus is considered available-for-sale. We did not hold any Level 2 and Level 3 assets or liabilities as of September 30, 2014 and December 31, 2013.
	The following table shows our financial assets measured at fair value, on a recurring basis, with money market funds recorded within cash and cash equivalents (in thousands):
		Quoted Prices in Active		Total Fair
		Markets for Identical		Value
		Instruments
		(Level 1)
	Money market fund at September 30, 2014	$	61,665	$	61,665
	Money market fund at December 31, 2013	$	65,708	$	65,708

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following (in thousands):
		September 30,		December 31,
		2014		2013
	Raw materials	$	11,158	$	10,765
	Work in process	883		534
	Finished goods	19,806		20,158
	Total	$	31,847	$	31,457

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		September 30,			December 31,
		2014			2013
	Equipment	$	42,738		$	40,180
	Furniture and fixtures	5,663			5,260
	Leasehold improvements	8,214			7,394
	Software	25,536			20,199
	Construction in process	3,935			2,649
	Total property and equipment	86,086			75,682
	Accumulated depreciation and amortization	(48,398		)	(40,428		)
	Total property and equipment, net	$	37,688		$	35,254
	Depreciation and amortization expense for property and equipment was approximately $2.9 million and $2.6 million for the three months ended September 30, 2014 and 2013, respectively, and $8.2 million and $8.2 million for the nine months ended September 30, 2014 and 2013, respectively.

Net_Investment_in_SalesType_Le

Net Investment in Sales-Type Leases	9 Months Ended
	Sep. 30, 2014
Net Investment in Sales-Type Leases [Abstract]	'
Net Investment Sales-Type Leases Disclosure	'
	Net Investment in Sales-Type Leases
	Our sales-type leases are for terms generally up to five years. Sales-type lease receivables are collateralized by the underlying equipment. The components of our net investment in sales-type leases are as follows (in thousands):
		September 30,			December 31,
		2014			2013
	Net minimum lease payments to be received	$	17,496		$	18,172
	Less unearned interest income portion	(1,108		)	(1,455		)
	Net investment in sales-type leases	16,388			16,717
	Less current portion	(5,565		)	(5,232		)
	Non-current net investment in sales-type leases	$	10,823		$	11,485
	The minimum lease payments under sales-type leases as of September 30, 2014 were as follows (in thousands):
	Remainder of 2014	$	1,614
	2015	5,746
	2016	4,412
	2017	3,465
	2018	1,889
	Thereafter	370
	Total	$	17,496
	The following table summarizes the credit losses and recorded investment in sales-type leases, excluding unearned interest (in thousands):
		Allowance for Credit Losses			Recorded Investment			Recorded Investment
					in Sales-type Leases Gross			in Sales-type Leases Net
	Credit loss disclosure for September 30, 2014:
	Accounts collectively evaluated for impairment	$	151		$	16,539		$	16,388
	Ending balances: September 30, 2014	$	151		$	16,539		$	16,388
	Credit loss disclosure for December 31, 2013:
	Accounts collectively evaluated for impairment	$	167		$	16,884		$	16,717
	Ending balances: December 31, 2013	$	167		$	16,884		$	16,717
	The following table summarizes the activity for the allowance for credit losses for the investment in sales-type leases (in thousands):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Allowance for credit losses, beginning of period	$	157		$	184		$	167		$	607
	Current period provision (reversal)	(6		)	15			(16		)	34
	Direct write-downs charged against the allowance	—			—			—			(413		)
	Recoveries of amounts previously charged off	—			(25		)	—			(54		)
	Allowance for credit losses, end of period	$	151		$	174		$	151		$	174

Business_Acquisition

Business Acquisition	9 Months Ended
	Sep. 30, 2014
Business Acquisition [Abstract]	'
Business Combination Disclosure [Text Block]	'
	Business Acquisition
	On August 22, 2014, we completed our acquisition of Surgichem, a wholly-owned subsidiary of Bupa Care Homes (CFG) plc ("Bupa") pursuant to an Agreement by and among Omnicell, Bupa and MTS (the "Share Purchase Agreement"), under which MTS, a wholly-owned subsidiary of Omnicell, purchased the entire issued share capital of Surgichem, with Omnicell acting as guarantor of MTS' obligations thereunder (the "Acquisition"). As a result of the Acquisition, Omnicell paid to Bupa $19.9 million in cash, subject to certain adjustments as provided for in the Share Purchase Agreement. Surgichem is in the process of being integrated with Omnicell’s existing UK business, MTS Medication Technologies Limited, a leading supplier of medication adherence packaging solutions.
	The Surgichem acquisition primarily was to align Omnicell with the long term trends of the healthcare market to manage the health of patients across the continuum of care, specifically in the UK market. We acquired all outstanding shares of Surgichem.
	We are accounting for the transaction under the acquisition method of accounting in accordance with the provisions of FASB Accounting Standards Codification ("ASC") Topic 805, Business Combinations. Under the acquisition method, the estimated fair value of the consideration transferred to purchase the acquired company is allocated to the assets acquired and the liabilities assumed based on their fair values. We have made significant estimates and assumptions in determining the allocation of the acquisition consideration. The acquisition consideration of $20.8 million is comprised of $19.9 million in cash at closing plus an estimated $0.9 million net working capital adjustment recorded in accrued liabilities, subject to review by Bupa and possible adjustment.
	The purchase price allocation is subject to certain post-closing working capital adjustments for the acquired current assets and current liabilities of Surgichem on the acquisition date. The total consideration, and the allocation of consideration to the individual net assets is preliminary, as there are remaining uncertainties to be resolved, including the settlement of the final net working capital adjustment.
	The total acquisition consideration was approximately $20.8 million and the preliminary acquisition price allocation was comprised of the following (in thousands):
		Fair Value Acquired
	Cash	$	153
	Accounts receivable	2,462
	Inventory	2,190
	Deferred tax assets and other current assets	361
	Total current assets	$	5,166
	Property and equipment	164
	Intangibles	5,730
	Goodwill	12,016
	Total assets	$	23,076
	Current liabilities	1,191
	Non-current deferred tax liabilities	1,104
	Total purchase price	$	20,781
	Acquired intangible assets. The fair value of $5.4 million for acquired customer relationships was determined based on an income approach using the discounted cash flow method. The fair value of $0.3 million for the trade name was determined using the relief-from-royalty approach. The intangible assets are being amortized over their estimated useful lives of 18 years for the customer relationships and just over one year for trade name.
	Goodwill. Approximately $12.0 million has been allocated to goodwill, which represents sales of future products and services and the assembled workforce of Surgichem. In accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other, goodwill will not be amortized, but instead will be tested for impairment at least annually or more frequently if certain indicators are present. In the event our management determines that the value of goodwill has become impaired, we will incur an accounting charge for the amount of impairment during the quarter in which the determination is made. We believe the Surgichem acquisition enhances Omnicell’s offerings and diversifies its revenue mix providing a more robust product and service solution to its current customers while expanding Omnicell’s international presence. We consider these factors as supporting the amount of goodwill recorded. Note that the amortization of intangible assets, and goodwill is not deductible for tax purposes. For the three months ended September 30, 2014, we incurred approximately $0.2 million in acquisition related costs related to the Surgichem acquisition, offset by a $0.5 million expense reimbursement from Bupa. For the nine months ended September 30, 2014, we incurred approximately $1.1 million in acquisition related costs related to the Surgichem acquisition, offset by a $0.5 million expense reimbursement from Bupa.These costs are included in selling, general and administrative expenses in our Condensed Consolidated Statement of Operations.
	During the three months ended September 30, 2014, the acquired Surgichem operations (consolidated since the August 22, 2014 acquisition date) generated approximately $1.4 million of revenue and impact on income from operations was $0.1 million.
	The total revenues of Surgichem for the nine months ended September 30, 2014 and 2013, were approximately $10.1 million (including the $1.4 million mentioned above) and $8.7 million, respectively. Results of operations for Surgichem have been included in our condensed consolidated financial statements subsequent to the date of acquisition and pro forma results of operations in accordance with authoritative guidance for prior periods have not been presented because the effect of the acquisition was not material to our prior period consolidated financial results.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	Goodwill
	Goodwill is tested for impairment at least annually or more frequently if events or circumstances indicate that an impairment loss may have occurred, and we write down these assets when impaired. We perform our annual impairment tests during the fourth quarter of each fiscal year using the closing balance sheet as of the last day of the third quarter.
	During the nine months ended September 30, 2014, we noted no indications of impairment or triggering events to cause us to perform a goodwill impairment analysis.
	Goodwill by reporting unit, which is the same for our operating segments, is as follows (in thousands):
		Goodwill at December 31, 2013		Goodwill Acquired		Translation Adjustments			Goodwill at September 30, 2014
	Reporting units:
	Automation and Analytics	$	28,543	$	—	$	—		$	28,543
	Medication Adherence	82,800		12,016		(269		)	94,547
	Total	$	111,343	$	12,016	$	(269	)	$	123,090
	Intangible Assets, net
	There were no indefinite-lived intangible assets as of September 30, 2014 or December 31, 2013. Finite-lived intangible assets consist of the following (in thousands):
		September 30, 2014							December 31, 2013
		Gross				Net			Gross				Net
		Carrying		Accumulated		Carrying			Carrying		Accumulated		Carrying		Amortization
		Amount		Amortization		Amount			Amount		Amortization		Amount		Life
	Finite-lived intangibles:
	Customer relationships	$	60,062	$	6,919	$	53,143		$	54,730	$	5,236	$	49,494	5-30 years
	Acquired technology	27,580		3,700		23,880			27,580		2,598		24,982		3-20 years
	Patents	1,658		338		1,320			1,493		254		1,239		20 years
	Trade name	7,193		1,461		5,732			6,890		1,003		5,887		1-12 years
	Non-compete agreements	60		60		—			60		60		—		3 years
	Total finite-lived intangibles	$	96,553	$	12,478	$	84,075		$	90,753	$	9,151	$	81,602
	Amortization expense for the intangible assets presented above was $1.2 million and $1.1 million for the three months ended September 30, 2014 and 2013, respectively, and $3.3 million and $3.2 million for the nine months ended September 30, 2014 and 2013, respectively. The amortization of acquired technology is included within product cost of sales and amortization of other acquired intangibles is included within selling, general and administrative expenses.
	Estimated future amortization expense of finite-lived intangible assets are as follows (in thousands):
	Remainder of 2014	$	1,289
	2015	4,980
	2016	4,355
	2017	4,267
	2018	4,113
	Thereafter	65,071
	Total	$	84,075

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2014
Accrued Liabilities, Current [Abstract]	'
Accrued Liabilities	'
	Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
		September 30,		December 31,
		2014		2013
	Rebates and lease buyouts	$	4,202	$	1,699
	Advance payments from customers	3,749		4,971
	Accrued Group Purchasing Organization (GPO) fees(1)	3,314		2,324
	Technology license purchase obligation, current portion	250		1,500
	Taxes payable	3,159		1,664
	Other	2,399		1,588
	Total	$	17,073	$	13,746
	(1) Fees paid pursuant to GPO agreements. Customers who buy our products pursuant to a GPO agreement obtain pre-negotiated contract terms and pricing.

Deferred_Gross_Profit

Deferred Gross Profit	9 Months Ended
	Sep. 30, 2014
Deferred Gross Profit [Abstract]	'
Deferred Gross Profit	'
	Deferred Gross Profit
	Deferred gross profit consists of the following (in thousands):
		September 30,			December 31,
		2014			2013
	Sales of medication and supply dispensing systems and packaging equipment(1)	$	48,669		$	29,040
	Cost of revenues, excluding installation costs	(13,127		)	(9,083		)
	Deferred gross profit	$	35,542		$	19,957
	(1) Sales that have been delivered and invoiced and not yet installed, or sales that have been shipped and not invoiced and not yet installed.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2014
Commitments [Abstract]	'
Commitments	'
	Commitments
	We lease properties in California, Florida, Illinois, Tennessee, and the United Kingdom. We also have smaller rented offices in Ohio, the United Arab Emirates, the People's Republic of China and the Federal Republic of Germany.
	At September 30, 2014, the minimum payments under our operating leases for each of the five succeeding fiscal years were as follows (in thousands):
	Remainder of 2014	$	1,448
	2015	5,604
	2016	5,192
	2017	4,468
	2018	4,298
	Thereafter	16,976
	Total	$	37,986
	We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. Our near-term commitments to our contract manufacturers and suppliers totaled $10.9 million as of September 30, 2014.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies
	Legal Proceedings
	On September 12, 2014, MV Circuit Design, Inc., an Ohio company, brought an action to correct the inventorship of certain patents owned by Omnicell, as well as related state-law claims against the Company in the Northern District of Ohio (Case No. 1:14-cv-02028-DAP) regarding allegations of fraud in the filing and prosecution of U.S. Patent Nos. 8,180,485, 8,773,270, 8,812,153, PCT/US2007/003765, PCT/US2011/063597, and PCT/US2011/0635505. Omnicell has been granted an extension to respond to the Original Complaint on November 14, 2014. No schedule has yet been set by the court. Omnicell is currently evaluating a response to this complaint and intends to defend the matter vigorously.
	As required under ASC 450, "Contingencies," we accrue for contingencies when we believe that a loss is probable and that we can reasonably estimate the amount of any such loss. We have not recorded any accrual for contingent liabilities associated with the legal proceedings described above based on our belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. We believe that we have valid defenses with respect to legal proceedings pending against us. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses.
	Guarantees
	As permitted under Delaware law and our certificate of incorporation and bylaws, we have agreed to indemnify our directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become our directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that we could be required to make under these indemnification agreements. We have purchased a directors’ and officers’ liability insurance policy that may enable us to recover a portion of any future payments that we may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers.
	Additionally, we undertake indemnification obligations in our ordinary course of business in connection with, among other things, the licensing of our products and the provision of our support services. In the ordinary course of our business, we have in the past and may in the future agree to indemnify another party, generally our business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, our gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, we attempt to limit the maximum potential amount of future payments that we may be required to make under these indemnification obligations to the amounts paid to us by a customer, but in some cases the obligation may not be so limited. In addition, we have in the past and may in the future warrant to our customers that our products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that our software media is free from material defects. Sales contracts for certain of our medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances we record have historically been immaterial.
	From time to time, we may also warrant that our professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. We generally seek to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, we would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. We have not been subject to any significant claims for such losses and have not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of September 30, 2014 or December 31, 2013.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Treasury Stock
	2012 Stock Repurchase Program
	On August 1, 2012, our Board of Directors established a stock repurchase program (the “2012 Repurchase Program”) authorizing share repurchases of up to $50.0 million of our common stock, with no termination date. The timing, price and volume of repurchases are to be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions or pursuant to a Rule 10b-18 plan. The 2012 Repurchase Program does not obligate us to repurchase any specific number of shares, and we may terminate or suspend the repurchase program at any time.
	For the nine months ended September 30, 2014, we repurchased a total of $19.6 million, or 721,101 shares, at an average cost of $27.23, including commissions. Of the repurchase activity, $2.6 million settled in October of 2014. For details regarding the 2012 Repurchase Program, please refer to Note 15, Stockholders' Equity, of our Annual Report on Form 10-K for the year ended December 31, 2013.
	From the inception of the 2012 Repurchase Program, we have repurchased a total of $40.6 million, or 1,605,746 shares at an average cost of $25.28 per share, including commissions. As of September 30, 2014, the maximum dollar value of shares that may yet be purchased under the plan is $9.4 million.

Stock_Option_Plans_and_ShareBa

Stock Option Plans and Share-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Option Plans and Share-Based Compensation	'
	Stock Option Plans and Share-Based Compensation
	Share-Based Plans
	Equity Incentive Plan
	For a detailed explanation of our stock plan and subsequent changes please refer to Note 16, Stock Option Plans, Share-Based Compensation and 401(k) Plan, of our Annual Report on Form 10-K for the year ended December 31, 2013.
	At September 30, 2014, 2,238,383 shares of common stock were reserved for future issuance our 2009 Equity Incentive Plan, as amended (the "2009 Plan"), and $5.8 million of total unrecognized compensation cost related to non-vested stock options was expected to be recognized over a weighted average period of 2.6 years.
	A summary of option activity under the 2009 Plan for the nine months ended September 30, 2014 is presented below:
	Options:		Number of Shares			Weighted-Average
						Exercise Price
			(in thousands)
	Outstanding at December 31, 2013		3,143			$15.82
	Granted		397			$26.14
	Exercised		(786	)		$14.44
	Forfeited		(72	)		$18.96
	Expired		(12	)		$19.88
	Outstanding at September 30, 2014		2,670			$17.66
	Vested and expected to vest at September 30, 2014		2,638			$17.60
	Exercisable at September 30, 2014		1,612			$15.47
	The aggregate intrinsic value of options exercised under our stock plans for the three and nine months ended September 30, 2014 was $2.5 million and $10.4 million, respectively, determined as of the date of option exercise.
	Restricted Stock and Restricted Stock Units
	A summary of activity of both restricted stock and restricted stock units ("RSUs") for the nine months ended September 30, 2014 is presented below:
		Restricted Stock						Restricted Stock Units
		Number of			Weighted-Average			Number of			Weighted-Average
		Shares			Grant Date			Shares			Grant Date
					Fair Value Per						Fair Value Per
					Share						Share
		(in thousands)						(in thousands)
	Non-vested, December 31, 2013	52			$18.43			362			$17.15
	Granted	38			$25.16			127			$25.73
	Vested	(54	)		$17.78			(118	)		$16.70
	Forfeited	—			—			(18	)		$16.15
	Non-vested, September 30, 2014	36			$26.47			353			$20.42
	The fair value of restricted stock is the product of the number of shares granted and the closing market price of our common stock on the grant date. Our unrecognized compensation cost related to non-vested restricted stock is approximately $6.8 million and is expected to be recognized over a weighted-average period of 2.5 years.
	Performance-Based Restricted Stock Units
	Performance-based restricted stock units ("PSUs") are an element of our executive compensation plans. In 2012, we granted 125,000 PSUs to our executive officers, of which 62,500 became eligible for vesting upon the achievement of a certain level of shareholder return for 2012 as described below. In 2013, we granted 137,500 PSUs to our executive officers, all of which became eligible for vesting upon the achievement of a certain level of shareholder return for the period from January 1, 2013 through February 28, 2014, as described below. In 2014, we granted 152,500 PSUs to our executive officers, all, none or a portion of which may become eligible for vesting depending on the level of shareholder return for 2014 and eligible for further time-based vesting based on the ranking of our total shareholder return. For a more detailed explanation of our PSUs and subsequent changes, please refer to Note 16, Stock Option Plans, Share-Based Compensation and 401(k) Plan on our Annual Report on Form 10-K for the year ended December 31, 2013.
	Our unrecognized compensation cost related to non-vested performance-based restricted stock units at September 30, 2014 was approximately $1.8 million and is expected to be recognized over a weighted-average period of 1.3 years. For the three months ended September 30, 2014 and 2013, we recognized $0.5 million and $0.4 million, respectively, of compensation expense for the PSUs. For the nine months ended September 30, 2014 and 2013, we recognized $1.5 million and $1.2 million, respectively, of compensation expense for the PSUs.
	The following table shows the percent of PSUs granted in 2012 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
	On January 22, 2013, the Compensation Committee of our Board of Directors ("the Compensation Committee") confirmed 35.3% as the percentile rank of Omnicell's 2012 total stockholder return. This resulted in 50% of the 2012 PSU awards, or 62,500 shares, as eligible for further time-based vesting. The eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares vested immediately on January 22, 2013 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
	The following table shows the percent of PSUs granted in 2013 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
	On March 20, 2014, the Compensation Committee confirmed 63.94% as the percentile rank of Omnicell's 2013-2014 total stockholder return. This resulted in 100% of the 2013 PSU awards, or 137,500 shares, as eligible for further time-based vesting. The eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares vested immediately on March 20, 2014 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
	On February 5, 2014, the Compensation Committee approved PSU awards of 132,500 shares. If the minimum performance threshold is met as determined by the Compensation Committee in 2015, the eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares will vest immediately, with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
	The following table shows the percent of PSUs granted in 2014 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
	A summary of activity of the PSUs for the nine months ended September 30, 2014 is presented below:
	Performance-based Stock Units	Number of Shares			Weighted-Average
					Grant Date
					Fair Value Per
					Share
		(in thousands)
	Non-vested, December 31, 2013	225			$13.32
Granted	155			$14.36
Vested	(74	)		$13.66
Forfeited	(28	)		$3.07
Non-vested, September 30, 2014	278			$14.84
1997 Employee Stock Purchase Plan
We have an Employee Stock Purchase Plan (the “ESPP”) under which eligible employees can purchase shares of our common stock based on a percentage of their compensation, but not greater than 15% of their earnings; provided, however, an eligible employees' right to purchase shares of our common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The purchase price per share is equal to the lower of 85% of the fair market value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period.
At the 2009 Annual Meeting of Stockholders, the stockholders approved an amendment to the ESPP, which added 2,622,426 shares to the reserve for future issuance. As of September 30, 2014, there were 619,616 shares reserved for future issuance under the ESPP. For the three months ended September 30, 2014, 227,275 shares of common stock were purchased under the ESPP. For the nine months ended September 30, 2014, 481,284 shares of common stock were purchased under the ESPP.
As of September 30, 2014, our unrecognized compensation cost related to the shares to be purchased under our ESPP was approximately $2.6 million and is expected to be recognized over a weighted average period of approximately 1.0 year.
Share-based Compensation
We account for share-based awards granted to employees and directors, including employee stock option awards, restricted stock, PSUs and RSUs issued pursuant to the 2009 Plan and employee stock purchases made under our ESPP using the estimated grant date fair value method of accounting in accordance with ASC 718, Stock Compensation.
We value options and ESPP shares using the Black-Scholes-Merton option-pricing model. Restricted stock and time-based RSUs are valued at the grant date fair value of the underlying common shares. The PSUs are valued via Monte Carlo simulation.
The following table shows a summary of the share-based compensation expense included in the condensed consolidated statements of operations (in thousands):
	Three Months Ended September 30,								Nine Months Ended September 30,
	2014				2013				2014		2013
Cost of revenues	$	441			$	325			$	973	$	955
Research and development	407				405				1,156		1,019
Selling, general and administrative	2,313				2,080				6,481		6,449
Total share-based compensation expenses	$	3,161			$	2,810			$	8,610	$	8,423

Segments

Segments	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segments	'
	Segments
	Prior to the first quarter of 2014, we organized our business into two operating business segments, the Acute Care and Non-Acute Care segments, which were based on the target customers for our products. The Acute Care segment primarily included products and services sold to hospital customers, and the Non-Acute Care segment primarily included products and services sold to customers outside of hospital settings.
	In the first quarter of 2014, we realigned our segments based on the products we sell, regardless of who they are sold to because our business has evolved to be managed more on a product basis, rather than on a customer-type basis. It has become more difficult to determine whether a customer is a hospital or a blend of hospitals and non-acute care facilities. We are at a point where many of our Acute Care and Non-Acute Care customers are converging to provide services across the continuum of care. These customers seek automation and analytics products that function across the various facilities they manage. We find ourselves providing solutions across multiple types of care environments. These customers are also interested in obtaining higher levels of adherence to prescribed medication regimens that our blister card products provide.
	Our two reportable segments are the Automation and Analytics segment and the Medication Adherence segment. The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. The Medication Adherence segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services.
	Prior period amounts in the tables below have been recast to conform to the way we internally manage and monitor performance at the segment level during the current period.
	We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (the "CODM") for making decisions and assessing performance as the source of our operating segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment, using information about its revenues, gross profit and income (loss) from operations. The CODM does not evaluate operating business segments using discrete asset information; accordingly, we do not report segment assets.
	Since 1992, Omnicell has provided automation and business information solutions to healthcare facilities in general, but with a focus on acute care hospitals. We have developed product solutions that help optimize various workflows utilized in hospitals. We have also developed sophisticated sales, installation, and service capabilities to serve the specific and special needs of hospitals. As the healthcare market evolves, acute care facilities are beginning to merge operationally with non-acute care facilities. The new healthcare organizations desire medication and supply inventory control and business analytics across the continuum of care environments they serve. Our Automation and Analytics segment represents the products we sell to fulfill these needs.
	Since 1984, MTS has provided medication adherence solutions to the non-acute care market. In 2012, we acquired MTS. The solutions supplied by MTS provide automated and semi-automated equipment to assist institutional and retail pharmacists in filling medication orders into blister cards, the primary method of medication control in non-acute care settings. Completing the product solution are the consumables used by institutional and retail pharmacists to make the medication adherence package. MTS has developed process manufacturing capabilities as well as sales capabilities to market medication adherence solutions to institutional and retail pharmacies. As healthcare evolves, these medication adherence solutions are finding application in acute care settings as well. Our Medication Adherence segment represents all the products we sell to fulfill medication adherence needs through blister cards, blister card packaging equipment, and related software.
	In August of 2014, we acquired Surgichem. Based in Stockport, UK, Surgichem is a provider of medication adherence packaging solutions to the UK care home and domiciliary care markets since 1989. Surgichem supplies its monitored dosage systems to a network of over 3,200 independent pharmacies and UK pharmacy chains. Surgichem is part of our Medication Adherence segment.
	The contributions of our operating segments to net revenues and income from operations, and the reconciliation to total net income, were as follows (amounts in thousands):
		Three Months Ended September 30, 2014									Three Months Ended September 30, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Total revenues	$	89,546		$	22,997		$	112,543		$	75,110		$	18,929		$	94,039
	Cost of revenues	38,412			14,585			52,997			30,240			11,759			41,999
	Gross profit	$	51,134		$	8,412		$	59,546		$	44,870		$	7,170		$	52,040
	Gross margin %	57.1		%	36.6		%	52.9		%	59.7		%	37.9		%	55.3		%
	Operating expenses	38,662			7,287			45,949			35,052			6,271			41,323
	Income from operations	$	12,472		$	1,125		$	13,597		$	9,818		$	899		$	10,717
	Operating margin %	13.9		%	4.9		%	12.1		%	13.1		%	4.7		%	11.4		%
	Interest and other income (expense), net							(706		)							25
	Income before provision for income taxes							12,891									10,742
	Provision for income taxes							5,591									2,987
	Net income							$	7,300								$	7,755
		Nine Months Ended September 30, 2014									Nine Months Ended September 30, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Total revenues	$	255,747		$	63,612		$	319,359		$	217,688		$	57,147		$	274,835
	Cost of revenues	109,345			39,933			149,278			92,465			35,595			128,060
	Gross profit	$	146,402		$	23,679		$	170,081		$	125,223		$	21,552		$	146,775
	Gross margin %	57.2		%	37.2		%	53.3		%	57.5		%	37.7		%	53.4		%
	Operating expenses	112,572			21,400			133,972			101,425			21,106			122,531
	Income from operations	$	33,830		$	2,279		$	36,109		$	23,798		$	446		$	24,244
	Operating margin %	13.2		%	3.6		%	11.3		%	10.9		%	0.8		%	8.8		%
	Interest and other income (expense), net							(1,003		)							(134		)
	Income before provision for income taxes							35,106									24,110
	Provision for income taxes							13,824									6,954
	Net income							$	21,282								$	17,156
	Segment depreciation and amortization, and capital expenditures were as follows (amounts in thousands):
		Three Months Ended September 30, 2014									Three Months Ended September 30, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Depreciation and amortization	$	3,460		$	1,854		$	5,314		$	2,805		$	1,683		$	4,488
	Capital expenditures	$	2,635		$	785		$	3,420		$	1,311		$	745		$	2,056
		Nine Months Ended September 30, 2014									Nine Months Ended September 30, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Depreciation and amortization	$	9,402		$	5,303		$	14,705		$	8,351		$	5,381		$	13,732
	Capital expenditures	$	8,802		$	1,953		$	10,755		$	3,329		$	4,478		$	7,807

Impairment_of_Software_Develop

Impairment of Software Development Costs	9 Months Ended
	Sep. 30, 2014
Asset Impairment [Abstract]	'
Impairment of Software Development Costs	'
	Impairment of Software Development Costs
	2013 Impairment
	As part of the continuing integration of MTS, in the first quarter of 2013, we reorganized our management team, including the software development department, within the Medication Adherence segment (formerly known as our Non-Acute segment). Through the end of the first quarter of 2013, the Medication Adherence segment had capitalized approximately $1.8 million of software development costs associated with a software solution under development which was intended to assist pharmacies in manual packaging of prescriptions. In connection with our financial statement close process for the quarter ended March 31, 2013, our management reassessed the viability of this project and the net realizable value of capitalized costs in light of its decision to change the related product road map and redesign this product based on evolving market demands. As part of this redesign process, new functionality and capabilities will need to be added to the product before commercialization. This redesign is intended to provide a more robust global platform providing larger scalability and significant functionality not contained in our current beta version. As such, we determined we can no longer support the technological feasibility of this project in conjunction with our software capitalization policy. Therefore, we charged these costs, in the amount of $1.8 million, ($0.03 per diluted share, net of tax), to expense as a component of research and development in the accompanying condensed consolidated statement of operations.

Credit_Agreement

Credit Agreement	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Credit Agreement	'
	Credit Agreement
	In September 2013, we entered into a credit agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, as administrative agent, and the lenders from time to time thereto. The Credit Agreement provides for a $75.0 million revolving credit facility with a $10.0 million letter of credit sub-limit. Loans under the Credit Agreement mature on September 25, 2018. The Credit Agreement permits us to request one or more increases in the aggregate commitments provided that such increases do not exceed $25.0 million in the aggregate. We expect to use the proceeds from any revolving loans under the credit facility for general corporate purposes, including future acquisitions. Our obligations under the Credit Agreement are guaranteed by certain of our domestic subsidiaries and secured by substantially all of our and the subsidiary guarantors’ assets.
	Amounts drawn under the Credit Agreement bear interest, at our election, at a Eurodollar rate plus a margin of 1.75% per annum, or an alternate base rate equal to the highest of (a) the prime rate, (b) the federal funds rate plus 0.50%, and (c) LIBOR for an interest period of one month plus 1.75%. We are required to pay a commitment fee of 0.25% per annum on the aggregate undrawn amount of the commitments under the credit facility.
	The Credit Agreement contains customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions. The Credit Agreement contains financial covenants that require us to, among other things, maintain a maximum consolidated total leverage ratio and a minimum consolidated fixed charge coverage ratio, in each case, as of the last day of each fiscal quarter.
	To date, we have not yet drawn any funds under the credit facility. We were in full compliance with all covenants at September 30, 2014 and for all periods since the commencement of the Credit Agreement.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	We provide for income taxes for each interim period based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 40.4% and 38.1% for the nine months ended September 30, 2014 and 2013, respectively. The increase in the estimated annual effective tax rate for the nine months ended September 30, 2014 compared to the same period in 2013 was primarily due to the expiration of the federal research and development credit as of December 31, 2013. The 2014 annual effective tax rate differed from the statutory rate of 35.0% primarily due to the unfavorable impact of state income taxes, non-deductible equity charges, and other non-deductible expenditures, which were partially offset by the domestic production activities deduction.
	The 2013 annual effective tax rate differed from the statutory rate of 35.0% primarily due to the unfavorable impact of state income taxes, non-deductible equity charges, and other non-deductible expenditures, which were partially offset by the federal research and development credit claimed and the domestic production activities deduction.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of presentation	'
	Basis of presentation. These interim condensed consolidated financial statements are unaudited but reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of Omnicell and our subsidiaries as of September 30, 2014, the results of our operations and comprehensive income for the three and nine months ended September 30, 2014 and 2013 and our cash flows for the nine months ended September 30, 2014 and 2013. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	Our results of operations, comprehensive income for the three and nine months ended September 30, 2014 and cash flows for the nine months ended September 30, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014, or for any future period.
Use of estimates	'
	Use of estimates. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, valuation of goodwill and purchased intangibles, valuation of long-lived assets and accounting for income taxes.
Principles of consolidation	'
	Principles of consolidation. The condensed consolidated financial statements include the accounts of our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation
Concentrations of credit risk	'
	Concentration of credit risk. Financial instruments that may potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents are maintained with several financial institutions and may exceed the amount of insurance provided on such balances. The majority of our accounts receivable are derived from sales to customers for commercial applications. We perform ongoing credit evaluations of our customers’ financial condition and limit the amount of credit extended when deemed necessary but generally require no collateral. We maintain reserves for potential credit losses. Our products are broadly distributed and there was no single customer accounting for 10% or more of revenues in the three and nine months ended September 30, 2014 and 2013. Additionally, there was no single customer accounting for 10% or more of accounts receivable at September 30, 2014 or December 31, 2013. We believe that we have no significant concentrations of credit risk at September 30, 2014.
Recently adopted and issued accounting standards	'
	Recently Adopted Accounting Standards
	In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ("ASU 2013-11"). ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. We adopted the amendments in ASU 2013-11 in the first quarter of 2014. This update did not have a significant impact on our financial position, operating results or cash flows.
	Recently Issued Accounting Standards
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers: Topic 606 ("ASU 2014-09"). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. Companies may use either of two methods: (i) full retrospective application to each prior reporting period presented with the option to elect certain practical expedients defined within ASU 2014-09; or (ii) modified retrospective application with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. ASU 2014-09 is effective for us in the first quarter of 2017 and we are currently evaluating the impact of our pending adoption on our consolidated financial statements.
Earnings per share	'
	Basic net income per share is computed by dividing net income for the period by the weighted average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Since their impact is anti-dilutive, we excluded 426,974 and 364,450 shares, respectively, from the calculations of diluted net income per share for the three and nine months ended September 30, 2014 and 465,301 and 1,178,755 shares, respectively, from the same calculations for the three and nine months ended September 30, 2013.
Share-based compensation	'
	We account for share-based awards granted to employees and directors, including employee stock option awards, restricted stock, PSUs and RSUs issued pursuant to the 2009 Plan and employee stock purchases made under our ESPP using the estimated grant date fair value method of accounting in accordance with ASC 718, Stock Compensation.
	We value options and ESPP shares using the Black-Scholes-Merton option-pricing model. Restricted stock and time-based RSUs are valued at the grant date fair value of the underlying common shares. The PSUs are valued via Monte Carlo simulation

Net_Income_Per_Share_Tables

Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	The calculation of basic and diluted net income per share is as follows (in thousands, except per share amounts):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Basic:
	Net income	$	7,300	$	7,755	$	21,282	$	17,156
	Weighted average shares outstanding — basic	35,994		35,133		35,634		34,499
	Net income per share — basic	$	0.2	$	0.22	$	0.6	$	0.5
	Diluted:
	Net income	$	7,300	$	7,755	$	21,282	$	17,156
	Weighted average shares outstanding — basic	35,994		35,133		35,634		34,499
	Add: Dilutive effect of employee stock plans	838		1,057		983		967
	Weighted average shares outstanding — diluted	36,832		36,190		$	36,617	35,466
	Net income per share — diluted	$	0.2	$	0.21	$	0.58	$	0.48

Cash_and_Cash_Equivalents_and_1

Cash and Cash Equivalents and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Schedule of Cash, Cash Equivalents and Investments	'
	Cash and cash equivalents consist of the following significant asset investment classes as of September 30, 2014 and December 31, 2013 (in thousands):
		September 30, 2014
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	42,522	$	—	$	—	$	42,522	$	42,522	N/A
	Money market fund	61,665		—		—		61,665		61,665		Available-for-sale
	Total cash and cash equivalents	$	104,187	$	—	$	—	$	104,187	$	104,187
	c	December 31, 2013
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	38,823	$	—	$	—	$	38,823	$	38,823	N/A
	Money market fund	65,708		—		—		65,708		65,708		Available-for-sale
	Total cash and cash equivalents	$	104,531	$	—	$	—	$	104,531	$	104,531
Fair Value, Assets Measured on Recurring Basis	'
	The following table shows our financial assets measured at fair value, on a recurring basis, with money market funds recorded within cash and cash equivalents (in thousands):
		Quoted Prices in Active		Total Fair
		Markets for Identical		Value
		Instruments
		(Level 1)
	Money market fund at September 30, 2014	$	61,665	$	61,665
	Money market fund at December 31, 2013	$	65,708	$	65,708

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventories consist of the following (in thousands):
		September 30,		December 31,
		2014		2013
	Raw materials	$	11,158	$	10,765
	Work in process	883		534
	Finished goods	19,806		20,158
	Total	$	31,847	$	31,457

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of Property, Plant and Equipment	'
	Property and equipment consist of the following (in thousands):
		September 30,			December 31,
		2014			2013
	Equipment	$	42,738		$	40,180
	Furniture and fixtures	5,663			5,260
	Leasehold improvements	8,214			7,394
	Software	25,536			20,199
	Construction in process	3,935			2,649
	Total property and equipment	86,086			75,682
	Accumulated depreciation and amortization	(48,398		)	(40,428		)
	Total property and equipment, net	$	37,688		$	35,254

Net_Investment_in_SalesType_Le1

Net Investment in Sales-Type Leases (Tables)	9 Months Ended
	Sep. 30, 2014
Net Investment in Sales-Type Leases [Abstract]	'
Components of Sales Type Lease Investments	'
	Our sales-type leases are for terms generally up to five years. Sales-type lease receivables are collateralized by the underlying equipment. The components of our net investment in sales-type leases are as follows (in thousands):
		September 30,			December 31,
		2014			2013
	Net minimum lease payments to be received	$	17,496		$	18,172
	Less unearned interest income portion	(1,108		)	(1,455		)
	Net investment in sales-type leases	16,388			16,717
	Less current portion	(5,565		)	(5,232		)
	Non-current net investment in sales-type leases	$	10,823		$	11,485
Schedule of Future Minimum Lease Payments for Capital Leases	'
	The minimum lease payments under sales-type leases as of September 30, 2014 were as follows (in thousands):
	Remainder of 2014	$	1,614
	2015	5,746
	2016	4,412
	2017	3,465
	2018	1,889
	Thereafter	370
	Total	$	17,496
Allowance for Credit Losses on Financing Receivables	'
	The following table summarizes the credit losses and recorded investment in sales-type leases, excluding unearned interest (in thousands):
		Allowance for Credit Losses			Recorded Investment			Recorded Investment
					in Sales-type Leases Gross			in Sales-type Leases Net
	Credit loss disclosure for September 30, 2014:
	Accounts collectively evaluated for impairment	$	151		$	16,539		$	16,388
	Ending balances: September 30, 2014	$	151		$	16,539		$	16,388
	Credit loss disclosure for December 31, 2013:
	Accounts collectively evaluated for impairment	$	167		$	16,884		$	16,717
	Ending balances: December 31, 2013	$	167		$	16,884		$	16,717
Schedule of Credit Losses Related to Financing Receivables, Noncurrent	'
	The following table summarizes the activity for the allowance for credit losses for the investment in sales-type leases (in thousands):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Allowance for credit losses, beginning of period	$	157		$	184		$	167		$	607
	Current period provision (reversal)	(6		)	15			(16		)	34
	Direct write-downs charged against the allowance	—			—			—			(413		)
	Recoveries of amounts previously charged off	—			(25		)	—			(54		)
	Allowance for credit losses, end of period	$	151		$	174		$	151		$	174

Business_Acquisition_Tables

Business Acquisition (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Acquisition, Pro Forma Information [Table Text Block]	'
	The total acquisition consideration was approximately $20.8 million and the preliminary acquisition price allocation was comprised of the following (in thousands):
		Fair Value Acquired
	Cash	$	153
	Accounts receivable	2,462
	Inventory	2,190
	Deferred tax assets and other current assets	361
	Total current assets	$	5,166
	Property and equipment	164
	Intangibles	5,730
	Goodwill	12,016
	Total assets	$	23,076
	Current liabilities	1,191
	Non-current deferred tax liabilities	1,104
	Total purchase price	$	20,781

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill	'
		Goodwill at December 31, 2013		Goodwill Acquired		Translation Adjustments			Goodwill at September 30, 2014
	Reporting units:
	Automation and Analytics	$	28,543	$	—	$	—		$	28,543
	Medication Adherence	82,800		12,016		(269		)	94,547
	Total	$	111,343	$	12,016	$	(269	)	$	123,090
	Intangible Assets, net
	There were no indefin
Schedule of Finite-Lived Intangible Assets	'
	There were no indefinite-lived intangible assets as of September 30, 2014 or December 31, 2013. Finite-lived intangible assets consist of the following (in thousands):
		September 30, 2014							December 31, 2013
		Gross				Net			Gross				Net
		Carrying		Accumulated		Carrying			Carrying		Accumulated		Carrying		Amortization
		Amount		Amortization		Amount			Amount		Amortization		Amount		Life
	Finite-lived intangibles:
	Customer relationships	$	60,062	$	6,919	$	53,143		$	54,730	$	5,236	$	49,494	5-30 years
	Acquired technology	27,580		3,700		23,880			27,580		2,598		24,982		3-20 years
	Patents	1,658		338		1,320			1,493		254		1,239		20 years
	Trade name	7,193		1,461		5,732			6,890		1,003		5,887		1-12 years
	Non-compete agreements	60		60		—			60		60		—		3 years
	Total finite-lived intangibles	$	96,553	$	12,478	$	84,075		$	90,753	$	9,151	$	81,602
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	'
	Estimated future amortization expense of finite-lived intangible assets are as follows (in thousands):
	Remainder of 2014	$	1,289
	2015	4,980
	2016	4,355
	2017	4,267
	2018	4,113
	Thereafter	65,071
	Total	$	84,075

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Accrued Liabilities, Current [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued liabilities consist of the following (in thousands):
		September 30,		December 31,
		2014		2013
	Rebates and lease buyouts	$	4,202	$	1,699
	Advance payments from customers	3,749		4,971
	Accrued Group Purchasing Organization (GPO) fees(1)	3,314		2,324
	Technology license purchase obligation, current portion	250		1,500
	Taxes payable	3,159		1,664
	Other	2,399		1,588
	Total	$	17,073	$	13,746

Deferred_Gross_Profit_Tables

Deferred Gross Profit (Tables)	9 Months Ended
	Sep. 30, 2014
Deferred Gross Profit [Abstract]	'
Schedule of Deferred Gross Profit	'
	Deferred gross profit consists of the following (in thousands):
		September 30,			December 31,
		2014			2013
	Sales of medication and supply dispensing systems and packaging equipment(1)	$	48,669		$	29,040
	Cost of revenues, excluding installation costs	(13,127		)	(9,083		)
	Deferred gross profit	$	35,542		$	19,957

Commitments_Tables

Commitments (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	At September 30, 2014, the minimum payments under our operating leases for each of the five succeeding fiscal years were as follows (in thousands):
	Remainder of 2014	$	1,448
	2015	5,604
	2016	5,192
	2017	4,468
	2018	4,298
	Thereafter	16,976
	Total	$	37,986

Stock_Option_Plans_and_ShareBa1

Stock Option Plans and Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Stock Options Roll Forward	'
	A summary of option activity under the 2009 Plan for the nine months ended September 30, 2014 is presented below:
	Options:		Number of Shares			Weighted-Average
						Exercise Price
			(in thousands)
	Outstanding at December 31, 2013		3,143			$15.82
	Granted		397			$26.14
	Exercised		(786	)		$14.44
	Forfeited		(72	)		$18.96
	Expired		(12	)		$19.88
	Outstanding at September 30, 2014		2,670			$17.66
	Vested and expected to vest at September 30, 2014		2,638			$17.60
	Exercisable at September 30, 2014		1,612			$15.47
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	'
	A summary of activity of both restricted stock and restricted stock units ("RSUs") for the nine months ended September 30, 2014 is presented below:
		Restricted Stock						Restricted Stock Units
		Number of			Weighted-Average			Number of			Weighted-Average
		Shares			Grant Date			Shares			Grant Date
					Fair Value Per						Fair Value Per
					Share						Share
		(in thousands)						(in thousands)
	Non-vested, December 31, 2013	52			$18.43			362			$17.15
	Granted	38			$25.16			127			$25.73
	Vested	(54	)		$17.78			(118	)		$16.70
	Forfeited	—			—			(18	)		$16.15
	Non-vested, September 30, 2014	36			$26.47			353			$20.42
PSU % eligible vesting vs Total Shareholder Return - Second year	'
	The following table shows the percent of PSUs granted in 2013 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
PSU % eligible vesting vs total Shareholder Return placement - First year	'
	The following table shows the percent of PSUs granted in 2012 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
Schedule of Nonvested Performance-based Units Activity	'
	A summary of activity of the PSUs for the nine months ended September 30, 2014 is presented below:
	Performance-based Stock Units	Number of Shares			Weighted-Average
					Grant Date
					Fair Value Per
					Share
		(in thousands)
	Non-vested, December 31, 2013	225			$13.32
	Granted	155			$14.36
	Vested	(74	)		$13.66
	Forfeited	(28	)		$3.07
	Non-vested, September 30, 2014	278			$14.84
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	'
	The following table shows a summary of the share-based compensation expense included in the condensed consolidated statements of operations (in thousands):
		Three Months Ended September 30,								Nine Months Ended September 30,
		2014				2013				2014		2013
	Cost of revenues	$	441			$	325			$	973	$	955
	Research and development	407				405				1,156		1,019
	Selling, general and administrative	2,313				2,080				6,481		6,449
	Total share-based compensation expenses	$	3,161			$	2,810			$	8,610	$	8,423

Segments_Tables

Segments (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	'
	The contributions of our operating segments to net revenues and income from operations, and the reconciliation to total net income, were as follows (amounts in thousands):
		Three Months Ended September 30, 2014									Three Months Ended September 30, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Total revenues	$	89,546		$	22,997		$	112,543		$	75,110		$	18,929		$	94,039
	Cost of revenues	38,412			14,585			52,997			30,240			11,759			41,999
	Gross profit	$	51,134		$	8,412		$	59,546		$	44,870		$	7,170		$	52,040
	Gross margin %	57.1		%	36.6		%	52.9		%	59.7		%	37.9		%	55.3		%
	Operating expenses	38,662			7,287			45,949			35,052			6,271			41,323
	Income from operations	$	12,472		$	1,125		$	13,597		$	9,818		$	899		$	10,717
	Operating margin %	13.9		%	4.9		%	12.1		%	13.1		%	4.7		%	11.4		%
	Interest and other income (expense), net							(706		)							25
	Income before provision for income taxes							12,891									10,742
	Provision for income taxes							5,591									2,987
	Net income							$	7,300								$	7,755
		Nine Months Ended September 30, 2014									Nine Months Ended September 30, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Total revenues	$	255,747		$	63,612		$	319,359		$	217,688		$	57,147		$	274,835
	Cost of revenues	109,345			39,933			149,278			92,465			35,595			128,060
	Gross profit	$	146,402		$	23,679		$	170,081		$	125,223		$	21,552		$	146,775
	Gross margin %	57.2		%	37.2		%	53.3		%	57.5		%	37.7		%	53.4		%
	Operating expenses	112,572			21,400			133,972			101,425			21,106			122,531
	Income from operations	$	33,830		$	2,279		$	36,109		$	23,798		$	446		$	24,244
	Operating margin %	13.2		%	3.6		%	11.3		%	10.9		%	0.8		%	8.8		%
	Interest and other income (expense), net							(1,003		)							(134		)
	Income before provision for income taxes							35,106									24,110
	Provision for income taxes							13,824									6,954
	Net income							$	21,282								$	17,156
Schedule of Segment Reporting Information, by Segment	'
	Segment depreciation and amortization, and capital expenditures were as follows (amounts in thousands):
		Three Months Ended September 30, 2014									Three Months Ended September 30, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Depreciation and amortization	$	3,460		$	1,854		$	5,314		$	2,805		$	1,683		$	4,488
	Capital expenditures	$	2,635		$	785		$	3,420		$	1,311		$	745		$	2,056
		Nine Months Ended September 30, 2014									Nine Months Ended September 30, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Depreciation and amortization	$	9,402		$	5,303		$	14,705		$	8,351		$	5,381		$	13,732
	Capital expenditures	$	8,802		$	1,953		$	10,755		$	3,329		$	4,478		$	7,807

Net_Income_Per_Share_Details

Net Income Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share	426,974	465,301	364,450	1,178,755
Basic:	'	'	'	'
Net income	$7,300	$7,755	$21,282	$17,156
Weighted Average Number of Shares Outstanding, Basic	35,994,000	35,133,000	35,634,000	34,499,000
Net income per share-basic	$0.20	$0.22	$0.60	$0.50
Diluted:	'	'	'	'
Weighted Average Number of Shares Outstanding, Basic	35,994,000	35,133,000	35,634,000	34,499,000
Dilutive Effect of Employee Stock Plans	$838	$1,057	$983	$967
Weighted Average Number of Shares Outstanding, Diluted	36,832,000	36,190,000	36,617,000	35,466,000
Net income per share - diluted	$0.20	$0.21	$0.58	$0.48

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies - Accounts Receivable Concentration (Details)	3 Months Ended	9 Months Ended
	Mar. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
	customer	customer	customer
Accounting Policies [Abstract]	'	'	'
Customers with 10% revenue concentration	0	0	'
Customers with 10 % accts rec concentration	'	0	0

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Significant Supplier Disclosure (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'
Purchases from significant supplier	$11	$8.60	$28.20	$22.50

Cash_and_Cash_Equivalents_and_2

Cash and Cash Equivalents and Fair Value of Financial Instruments - Schedule of Cash and Cash Equivalents (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents, Amortized Cost	$104,187	$104,531	$116,190	$62,313
Cash, cash equiv and S-T-I: Amortized cost	104,187	104,531	'	'
Cash, cash equiv and S-T-I: Gross unrealized gains	0	0	'	'
Cash, cash equiv and S-T-I: Gross unrealized losses	0	0	'	'
Cash, Cash Equivalents, and Short-term Investments	104,187	104,531	'	'
Cash	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents, Amortized Cost	42,522	38,823	'	'
Cash and cash equivalents - gross unrealized gain	0	0	'	'
Cash and cash equivalents - Gross unrealized losses	0	0	'	'
Cash and Cash Equivalents, Fair Value Disclosure	42,522	38,823	'	'
Money Market Funds	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents, Amortized Cost	61,665	65,708	'	'
Cash and cash equivalents - gross unrealized gain	0	0	'	'
Cash and cash equivalents - Gross unrealized losses	0	0	'	'
Cash and Cash Equivalents, Fair Value Disclosure	61,665	65,708	'	'
Cash and Cash Equivalents	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash, Cash Equivalents, and Short-term Investments	104,187	104,531	'	'
Cash and Cash Equivalents | Cash	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	42,522	38,823	'	'
Cash and Cash Equivalents | Money Market Funds	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$61,665	$65,708	'	'

Cash_and_Cash_Equivalents_and_3

Cash and Cash Equivalents and Fair Value of Financial Instruments - Assets Measured at Fair Value (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
		Money Market Funds	Money Market Funds	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]
				Money Market Funds	Money Market Funds	Fair Value, Inputs, Level 1 [Member]	Fair Value, Inputs, Level 1 [Member]
						Money Market Funds	Money Market Funds
Cash and Cash Equivalents [Line Items]	'	'	'	'	'	'	'
Money Market Fund - daily traded value	$1	'	'	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	$61,665,000	$65,708,000	$61,665,000	$65,708,000	$61,665,000	$65,708,000

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Abstract]	'	'
Raw materials	$11,158	$10,765
Work in process	883	534
Finished goods	19,806	20,158
Total	$31,847	$31,457

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and Equipment, Gross	$86,086,000	'	'	$75,682,000
Accumulated Depreciation	-48,398,000	'	'	-40,428,000
Property and equipment, net	37,688,000	'	'	35,254,000
Depreciation expense	2,900,000	2,600,000	8,200,000	'
Equipment [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and Equipment, Gross	42,738,000	'	'	40,180,000
Furniture and Fixtures [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and Equipment, Gross	5,663,000	'	'	5,260,000
Leasehold Improvements [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and Equipment, Gross	8,214,000	'	'	7,394,000
Software [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and Equipment, Gross	25,536,000	'	'	20,199,000
Construction in Progress [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Property and Equipment, Gross	$3,935,000	'	'	$2,649,000

Net_Investment_in_SalesType_Le2

Net Investment in Sales-Type Leases - Components of Sales-Type Leases (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Dec. 31, 2013
Net Investment in Sales-Type Leases [Abstract]	'		'
Sales type leases, lease term	'5 years		'
Capital Leases, Net Investment in Sales Type Leases [Abstract]	'		'
Net minimum lease payments to be received	$17,496		$18,172
Less unearned interest income portion	-1,108		-1,455
Net investment in sales-type leases	16,388		16,717
Less current portion	-5,565	[1]	5,232	[1]
Non-current net investment in sales-type leases	$10,823		$11,485
[1]	{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjU4OTZiYThmOTBlYjRhOTY4NjJhOWRhMDI1YzExMzg5fFRleHRTZWxlY3Rpb246MzE0RDA0QTQ5MzU4Rjc1OEFFRUEyRTZGMDZDOEY2N0EM}

Net_Investment_in_SalesType_Le3

Net Investment in Sales-Type Leases - Minimum Lease Payments Under Sales-Type Leases (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Net Investment in Sales-Type Leases [Abstract]	'
Remainder of 2014	$1,614
2015	5,746
2016	4,412
2017	3,465
2018	1,889
Thereafter	370
Total	$17,496

Net_Investment_in_SalesType_Le4

Net Investment in Sales-Type Leases - Credit Losses and Recorded Investment in Sales-Type Leases (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Net Investment in Sales-Type Leases [Abstract]	'	'	'	'	'	'
Financing Receivable, Allowance for Credit Losses, Collectively Evaluated for Impairment	$151	'	$167	'	'	'
Financing Receivable Gross - collectively evalauated for impairment	16,539	'	16,884	'	'	'
Financing Receivable, Collectively Evaluated for Impairment	16,388	'	16,717	'	'	'
Financing Receivable, Allowance for Credit Losses	151	157	167	174	184	607
Financing Receivable, Gross	16,539	'	16,884	'	'	'
Financing Receivable, Net	$16,388	'	$16,717	'	'	'

Net_Investment_in_SalesType_Le5

Net Investment in Sales-Type Leases - Allowance for Credit Losses (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Mar. 31, 2013
Financing Receivable, Allowance for Credit Losses [Roll Forward]	'	'	'	'	'	'
Allowance for credit losses, beginning of period	'	'	$167	$607	$157	$184
Current period provision (reversal)	-6	15	-16	34	'	'
Direct write-downs charged against the allowance	0	0	0	-413	'	'
Recoveries of amounts previously charged off	0	-25	0	-54	'	'
Allowance for credit losses, end of period	$151	$174	$151	$174	$157	$184

Business_Acquisition_Details

Business Acquisition (Details) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended		3 Months Ended		0 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Aug. 22, 2014	Sep. 30, 2014	Aug. 22, 2014	Aug. 22, 2014	Aug. 22, 2014
							MTS-Medication Technologies [Member]	MTS-Medication Technologies [Member]	Customer Relationships [Member]	Trade Names [Member]
									MTS-Medication Technologies [Member]	MTS-Medication Technologies [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'
Acquistiion consideration accrued as goodwill and accrued liabilities	'	$860,000	'	$0	'	'	'	'	'	'
Business Acquisition cost reimbursement	'	'	-500,000	'	'	'	'	'	'	'
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	1,400,000	'	'	'	'	'	'	'	'	'
Business Combination, Separately Recognized Transactions, Net Gains and Losses	100,000	'	'	'	'	'	'	'	'	'
Business Acquisition, Pro Forma Revenue	'	'	10,100,000	'	'	'	'	'	'	'
Business Acquisition, Revenue Reported by Acquired Entity for Last Annual Period	'	'	'	'	8,700,000	'	'	'	'	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	'	'	'	'	'	5,730,000	'	'	'	'
Business acquisition cash paid at closing	'	'	'	'	'	'	'	19,900,000	'	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	'	'	'	'	'	23,076,000	'	'	'	'
Business Combination, Consideration Transferred	'	'	'	'	'	'	20,800,000	'	'	'
Finite-lived Intangible Assets Acquired	'	'	'	'	'	'	'	'	5,420,000	310,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	'	'	'	'	'	12,016,000	'	'	'	'
Business Combination, Acquisition Related Costs	'	200,000	1,100,000	'	'	'	'	'	'	'
Business Acquisition Final adjustment amount, estimated	'	'	'	'	'	'	$900,000	'	'	'

Business_Acquisition_Bus_Acq_t

Business Acquisition Bus Acq - tranasaction costs expense in period (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Business Acquisition [Line Items]	'	'
Business Combination, Acquisition Related Costs	$0.20	$1.10

Business_Acquisition_Business_

Business Acquisition Business Acquisition PPA (Details) (USD $)	Aug. 22, 2014
In Thousands, unless otherwise specified
Business Combinations [Abstract]	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	$153
Business Combination, Acquired Receivables, Fair Value	2,462
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	2,190
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets	361
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	5,166
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	164
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	5,730
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	12,016
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	23,076
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	1,191
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent	1,104
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	$20,781

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Goodwill Rollforward by Segment (details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
		Automation and Analytics	Medication Adherence	Medication Adherence
Goodwill [Roll Forward]	'	'	'	'
Goodwill, Beginning balance	$111,343	$28,543	$94,547	$82,800
Goodwill acquired	12,016	0	'	'
Goodwill, Ending balance	$123,090	$28,543	$94,547	$82,800

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets - Intangible Assets, Net (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

In Thousands, unless otherwise specified

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Acquired technology [Member]

Acquired technology [Member]

Acquired technology [Member]

Acquired technology [Member]

Patents [Member]

Patents [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Noncompete Agreements [Member]

Noncompete Agreements [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Gross

$96,553

$90,753

$60,062

$54,730

'

'

$27,580

$27,580

'

'

$1,658

$1,493

$7,193

$6,890

'

'

$60

$60

Finite-Lived Intangible Assets, Accumulated Amortization

12,478

9,151

6,919

5,236

'

'

3,700

2,598

'

'

338

254

1,461

1,003

'

'

60

60

Finite-Lived Intangible Assets, Net

$84,075

$81,602

$53,143

$49,494

'

'

$23,880

$24,982

'

'

$1,320

$1,239

$5,732

$5,887

'

'

$0

$0

Finite-Lived Intangible Asset, Useful Life

'

'

'

'

'5 years

'30 years

'

'

'3 years

'20 years

'20 years

'

'

'

'3 years

'12 years

'3 years

'

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets - Narrative (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'	'	'
Indefinite-Lived Intangible Assets	'	'	'	'	$0	$0
Amortization of Intangible Assets	$1,100,000	$1,100,000	$3,300,000	$3,200,000	'	'

Goodwill_and_Other_Intangible_5

Goodwill and Other Intangible Assets - Future Amortization of Intangible Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Remainder of 2014	$1,289	'
2015	4,980	'
2016	4,355	'
2017	4,267	'
2018	4,113	'
Thereafter	65,071	'
Finite-Lived Intangible Assets, Net	$84,075	$81,602

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities, Current [Abstract]	'		'
Rebates and lease buyouts	$4,202		$1,699
Advance payments from customers	3,749		4,971
Accrued Group Purchasing Organization (GPO) fees(1)	3,314	[1]	2,324	[1]
Technology license purchase obligation, current portion	250		1,500
Taxes payable	3,159		1,664
Other	2,399		1,588
Total	$17,073		$13,746
[1]	Fees paid pursuant to GPO agreements. Customers who buy our products pursuant to a GPO agreement obtain pre-negotiated contract terms and pricing.

Deferred_Gross_Profit_Details

Deferred Gross Profit (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Gross Profit [Abstract]	'		'
Sales of medication and supply dispensing systems and packaging equipment(1)	$48,669	[1]	$29,040	[1]
Cost of revenues, excluding installation costs	-13,127		-9,083
Deferred gross profit	$35,542		$19,957
[1]	Sales that have been delivered and invoiced and not yet installed, or sales that have been shipped and not invoiced and not yet installed.

Commitments_Details

Commitments (Details) (USD $)	Sep. 30, 2014
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'
Remainder of 2014	$1,448,000
2015	5,604,000
2016	5,192,000
2017	4,468,000
2018	4,298,000
Thereafter	16,976,000
Total	37,986,000
Purchase commitment, remaining minimum amount committed	$10,900,000

Contingencies_Details

Contingencies (Details)	9 Months Ended
	Sep. 30, 2014
Product Liability Contingency [Line Items]	'
Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining	'30 days
Medication Packaging Systems	'
Product Liability Contingency [Line Items]	'
Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining	'6 months

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended	26 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
					2012 Repurchase Program	2012 Repurchase Program	2012 Repurchase Program
Class of Stock [Line Items]	'	'	'	'	'	'	'
Stock repurchase program, authorized amount	'	'	'	'	'	$50,000,000	'
Payments for repurchase of common stock	'	'	17,052,000	0	19,600,000	'	40,600,000
Allocated share-based compensation expense	3,161,000	2,810,000	8,610,000	8,423,000	'	'	'
Treasury stock, shares acquired	'	'	'	'	721,101	'	1,605,746
Treasury stock, average cost per share	'	'	'	'	$27.23	'	$25.28
Treasury Stock in accrued liabilities	2,586,000	'	'	'	'	'	'
Stock repurchase program, remaining authorized repurchase amount	'	'	'	'	$9,400,000	'	'

Stock_Option_Plans_and_ShareBa2

Stock Option Plans and Share-Based Compensation - Narrative (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2012

Jan. 22, 2013

Dec. 31, 2012

Mar. 20, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Mar. 31, 2014

Restricted Stock

Restricted Stock

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Employee Stock [Member]

Employee Stock [Member]

2009 Equity Incentive Plan

2009 Equity Incentive Plan

Below the 75th percentile ranking [Member]

Below the 75th percentile ranking [Member]

2012 PSU

2012 PSU

2013 PSU

2013 PSU

2013 PSU

Stock Options

Minimum [Member]

Maximum [Member]

PSU program year one [Member]

PSU program year one [Member]

Performance-Based Restricted Stock Units

Performance-Based Restricted Stock Units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

PSU percentage eligible for time-based vesting

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110.00%

119.00%

Capital shares reserved for future issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

619,616

619,616

2,238,383

'

'

'

Compensation cost not yet recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,800,000

'

'

Compensation cost not yet recognized, period for recognition

'

'

'

'

'2 years 6 months

'

'

'

'1 year 3 months 6 days

'

'

'

'

'

'

'

'

'

'

'2 years 7 months 6 days

'

'

Options, exercises in period, intrinsic value

2,500,000

'

10,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation costs not yet recognized

'

'

'

'

6,800,000

6,800,000

1,800,000

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Awards granted

'

'

'

'

'

38,000

'

'

155,000

'

'

'

125,000

'

132,500

152,500

'

'

'

'

'

'

Number of shares eligible for vesting

'

'

'

'

'

'

'

'

'

'

62,500

'

'

'

'

'

'

'

'

'

'

'

PSU shares eligible for vesting based on actual shareholder return

'

'

'

'

'

'

'

'

'

'

'

62,500

'

137,500

'

'

'

'

'

'

'

'

Allocated share-based compensation expense

$3,161,000

$2,810,000

$8,610,000

$8,423,000

'

'

$500,000

$400,000

$1,500,000

$1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

Percentile ranking of 2012 shareholder return

'

'

'

'

'

'

'

'

'

'

'

35.30%

'

'

'

'

'

'

'

'

'

'

PSU percentage eligible for vesting based on actual return

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

100.00%

'

'

'

'

'

'

'

'

First year share vesting rate

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

25.00%

'

'

'

'

'

'

'

'

Percentile ranking of 2013 shareholder return

'

'

'

'

'

'

'

'

'

'

'

'

'

63.94%

'

'

'

'

'

'

'

'

Shares issued in period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

227,275

481,284

'

'

'

'

Stock_Option_Plans_and_ShareBa3

Stock Option Plans and Share-Based Compensation - Stock Option Rollforward (Details) (Stock Options, USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014
Stock Options	'
Options, Number of Shares:	'
Outstanding at beginning of period	3,143
Granted	397
Exercised	-786
Forfeited	-72
Expired	-12
Outstanding at end of period	2,670
Vested and expected to vest	2,638
Exercisable	1,612
Options, Weighted-Average Exercise Price (in dollars per share):	'
Outstanding, beginning of period	$15.82
Granted	$26.14
Exercised	$14.44
Forfeited	$18.96
Expired	$19.88
Outstanding, end of period	$17.66
Vested and expected to vest	$17.60
Exercisable	$15.47

Stock_Option_Plans_and_ShareBa4

Stock Option Plans and Share-Based Compensation - Restricted Stock Awards and RSUs rollforward (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Restricted Stock	'
Number of Shares:	'
Nonvested, Beginning Balance	52,000
Granted	38,000
Vested	-54,000
Forfeited	0
Nonvested, Ending Balance	36,000
Weighted-Average Grant Date Fair Value Per Share (in dollars per share):	'
Nonvested, Beginning Balance	$18.43
Granted	$25.16
Vested	$17.78
Forfeited	$0
Nonvested, Ending Balance	$26.47
Restricted Stock Units	'
Number of Shares:	'
Nonvested, Beginning Balance	362,000
Granted	127,000
Vested	-118,000
Forfeited	-18,000
Nonvested, Ending Balance	353,000
Weighted-Average Grant Date Fair Value Per Share (in dollars per share):	'
Nonvested, Beginning Balance	$17.15
Granted	$25.73
Vested	$16.70
Forfeited	$16.15
Nonvested, Ending Balance	$20.42

Stock_Option_Plans_and_ShareBa5

Stock Option Plans and Share-Based Compensation - Percent of PSUs Granted (Details) (PSU Program Year Three, Performance-Based Restricted Stock Units)	9 Months Ended
	Sep. 30, 2014
Below the 35th percentile	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
PSU percentage eligible for time-based vesting	0.00%
At least the 35th percentile, but below the 50th percentile	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
PSU percentage eligible for time-based vesting	50.00%
At least the 50th percentile	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
PSU percentage eligible for time-based vesting	100.00%

Stock_Option_Plans_and_ShareBa6

Stock Option Plans and Share-Based Compensation - PSU Rollforward (Details) (Performance-Based Restricted Stock Units, USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Performance-Based Restricted Stock Units	'	'
Number of Shares:	'	'
Nonvested, Beginning Balance	225,000	'
Granted	155,000	'
Vested	-74,000	'
Forfeited	-28,000	'
Nonvested, Ending Balance	278,000	'
Weighted-Average Grant Date Fair Value Per Share (in dollars per share):	'	'
Nonvested, Beginning Balance	$13.32	'
Granted	'	$14.36
Vested	'	$13.66
Forfeited	'	$3.07
Nonvested, Ending Balance	'	$14.84

Stock_Option_Plans_and_ShareBa7

Stock Option Plans and Share-Based Compensation - ESPP- Employee stock purchase plan (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Employee Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
ESPP max percent of earnings contributable	'	15.00%
ESPP purchase price as percent of begin and-or ending fair value	'	85.00%
Capital shares reserved for future issuance	619,616	619,616
Shares issued in period	227,275	481,284
Employee Stock Purchase Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of additional shares authorized	'	2,622,426
Compensation not yet recognized	2.6	2.6
Compensation cost not yet recognized, period for recognition	'	'1 year

Stock_Option_Plans_and_ShareBa8

Stock Option Plans and Share-Based Compensation - Stock expense by P&L caption (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated share-based compensation expense	$3,161	$2,810	$8,610	$8,423
Cost of revenues	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated share-based compensation expense	441	325	973	955
Research and development	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated share-based compensation expense	407	405	1,156	1,019
Selling, general and administrative	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated share-based compensation expense	$2,313	$2,080	$6,481	$6,449

Segments_Reconciliation_of_Ope

Segments - Reconciliation of Operationg Profit (Loss) from Segments to Consolidated (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			segment
Segment Reporting Information [Line Items]	'	'	'	'
Number of Reportable Segments	'	'	2	'
Revenues	$112,543	$94,039	$319,359	$274,835
Cost of Revenue	52,997	41,999	149,278	128,060
Gross profit	59,546	52,040	170,081	146,775
Gross Margin Percentage	52.90%	55.30%	53.30%	53.40%
Operating Expenses	45,949	41,323	133,972	122,531
Operating Income (Loss)	13,597	10,717	36,109	24,244
Operating margin percentage	12.10%	11.40%	11.30%	8.80%
Interest and other income (expense), net	-706	25	-1,003	-134
Income before provision for income taxes	12,891	10,742	35,106	24,110
Provision for income taxes	5,591	2,987	13,824	6,954
Net income	7,300	7,755	21,282	17,156
Medication Adherence	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	22,997	18,929	63,612	57,147
Cost of Revenue	14,585	11,759	39,933	35,595
Gross profit	8,412	7,170	23,679	21,552
Gross Margin Percentage	36.60%	37.90%	37.20%	37.70%
Operating Expenses	7,287	6,271	21,400	21,106
Operating Income (Loss)	1,125	899	2,279	446
Operating margin percentage	4.90%	4.70%	3.60%	0.80%
Automation and Analytics	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	89,546	75,110	255,747	217,688
Cost of Revenue	38,412	30,240	109,345	92,465
Gross profit	51,134	44,870	146,402	125,223
Gross Margin Percentage	57.10%	59.70%	57.20%	57.50%
Operating Expenses	38,662	35,052	112,572	101,425
Operating Income (Loss)	$12,472	$9,818	$33,830	$23,798
Operating margin percentage	13.90%	13.10%	13.20%	10.90%

Segments_Deprecation_and_Amort

Segments - Deprecation and Amortization and Capital Expenditures (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization	$5,314	$4,488	$14,705	$13,732
Capital Expenditures	3,420	2,056	10,755	7,807
Automation and Analytics [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization	3,460	2,805	9,402	8,351
Capital Expenditures	2,635	1,311	8,802	3,329
Medication Adherence	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization	1,854	1,683	5,303	5,381
Capital Expenditures	$785	$745	$1,953	$4,478

Impairment_of_Software_Develop1

Impairment of Software Development Costs (Details) (USD $)	3 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013
Asset Impairment [Abstract]	'	'	'
Impairment of software development costs	'	$0	$1,759
Change in accounting estimate impact on dilted eps	$0.03	'	'

Credit_Agreement_Details

Credit Agreement (Details) (USD $)	3 Months Ended
	Sep. 30, 2014
Line of Credit Facility [Line Items]	'
Line of credit, maximum borrowing capacity	$75,000,000
Line of credit, unused capacity, commitment fee percentage	0.25%
Potential Increase in Aggregate Commitments [Member]	'
Line of Credit Facility [Line Items]	'
Line of credit, maximum borrowing capacity	25,000,000
Letter of Credit [Member]	'
Line of Credit Facility [Line Items]	'
Line of credit, maximum borrowing capacity	$10,000,000
Eurodollar Rate [Member]	'
Line of Credit Facility [Line Items]	'
Basis spread on variable rate	1.75%
Federal Funds Rate [Member]	'
Line of Credit Facility [Line Items]	'
Basis spread on variable rate	0.50%
LIBOR [Member]	'
Line of Credit Facility [Line Items]	'
Basis spread on variable rate	1.75%

Income_Taxes_Details

Income Taxes (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'
effective tax rate before discrete items	40.40%	38.10%
Effective income tax rate reconciliation, statutory rate	35.00%	'